Macro Finance
Gilead-Backed Aspen Neuroscience Shares Dip 0.7% After IPO
Bloomberg Markets·October 30, 2026·1 min read
Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 0.7% after raising about $140.6 million in a US initial public offering. The modest decline contrasts with recent biotech IPOs, suggesting tepid investor demand for the company's pipeline of experimental treatments.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.